Related references
Note: Only part of the references are listed.History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
Albina N. Minlikeeva et al.
CANCER CAUSES & CONTROL (2017)
Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study
Seiko Otokozawa et al.
Asian Pacific Journal of Cancer Prevention (2015)
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Seiji Mabuchi et al.
GYNECOLOGIC ONCOLOGY (2015)
Altered Mucins (MUC) Trafficking in Benign and Malignant Conditions
Suhasini Joshi et al.
ONCOTARGET (2014)
Endometriosis and Ovarian Cancer Risk: A Systematic Review of Epidemiological Studies
Menelaos Zafrakas et al.
FRONTIERS IN SURGERY (2014)
Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment
Hadas Reuveni et al.
CANCER RESEARCH (2013)
The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Zachary C. Dobbin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review
Simona Ferraro et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis
Fake Li et al.
BMC CANCER (2012)
Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs)
N. Mitic et al.
DISEASE MARKERS (2012)
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Francis Jacob et al.
GYNECOLOGIC ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Ultrasound Evaluation of Gynecologic Causes of Pelvic Pain
Lawrence A. Cicchiello et al.
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA (2011)
Prevalence, incidence, and natural history of simple ovarian cysts among women >55 years old in a large cancer screening trial
Robert T. Greenlee et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2010)
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Jennifer A. Belisle et al.
MOLECULAR CANCER (2010)
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Raffit Hassan et al.
LUNG CANCER (2010)
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
K. Huhtinen et al.
BRITISH JOURNAL OF CANCER (2009)
A Binding Domain on Mesothelin for CA125/MUC16
Osamu Kaneko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses
A. Sokalska et al.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2009)
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2006)
N-glycosylation of the MUC1 mucin in epithelial cells and secretions
Simon Parry et al.
GLYCOBIOLOGY (2006)
Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia
K Shibata et al.
GYNECOLOGIC ONCOLOGY (2005)
O-glycosylation of the mucin type
FA Hanisch
BIOLOGICAL CHEMISTRY (2001)
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
PC Prorok et al.
CONTROLLED CLINICAL TRIALS (2000)
Share Paper
